S9031-S9126-S9333-S9500-A, Examination of the Prognostic Significance of AML-Specific and Age-Associated Genes in AML Patients
- To determine whether the expression of previously identified acute myeloid leukemia
(AML)-specific and age-associated genes have prognostic significance in adult patients
- To examine, preliminarily, if AML-specific and age-associated expression changes occur
in the most primitive hematopoietic leukemia blasts (i.e., CD34+/38-).
- To examine, preliminarily, whether methylation or histone modification of the IRF8 CPG
island/promoter region is correlated with IRF8 gene expression in AML.
OUTLINE: This is a multicenter study.
Previously collected specimens of RNA from pre-treatment marrow or peripheral blood are
obtained from a repository of SWOG clinical trials (SWOG-S9031, SWOG-9126, SWOG-9333, and
SWOG-9500). Samples are analyzed for absolute expression levels of 23 selected genes and
relative expression levels of splice variants via quantitative RT/PCR and GeneScan assays
and linked to clinical and outcome data from the main SWOG database. Samples from a subset
of patients are analyzed to confirm aberrant expression of acute myeloid leukemia-specific
and age-associated genes in highly enriched population of leukemic blasts (CD34+/CD38- and
CD34+/CD38+). DNA samples are also analyzed for correlation of IRF8 gene expression with
methylation or histone modification of the IRF8 CPG island/promoter region.
Time Perspective: Retrospective
Prognostic significance for complete response, overall survival, and relapse-free survival of total and relative expression levels (variant/wild type ratios) for each gene
Derek L. Stirewalt, MD
Fred Hutchinson Cancer Research Center
United States: Federal Government